Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Int J Drug Policy. 2020 Mar 9;88:102710. doi: 10.1016/j.drugpo.2020.102710

Figure 4. Future projections of HCV incidence among PWID in Tijuana with: status quo scenario, combination harm reduction elimination scenario (DAAs plus OAT+HCNSP at 50% coverage), and combination intervention but harm reduction removal in 2025.

Figure 4.

Lines present mean values from 1,000 simulations. Dashed lines show 2.5 and 97.5% centile predictions from the baseline scenario. DAA: Direct-acting antiviral treatment; OAT: Opiate agonist therapy; HCNSP: Needle/syringe exchange program.